We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Explore
Renal Cell Carcinoma
Center of Excellence
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
No comments yet, be the first to start the discussion!
Eric Wiedower
Apr 07, 2015
Patient was found to have metastatic renal cell with 90% sarcomatoid features and 10% clear cell. According to NCCN there are multiple options for this patient with predominantly non-clear cell histology which include the following:
Clinical trial
Temsirolimus
Sorafenib
Sunitinib
Pazopanib
Axitinib
Everolimus
Erolitinib
Bevacizumab
Targeted therapies have predominantly been studied in clear cell RCC due to predominance of this histological subtype. This patient was started on pazopanib 800mg qday which has also shown activity in soft tissue sarcomas. Ongoing clinical trials are underway investigating the efficacy of pazopanib in non-clear cell histology. A phase III, open-label, multicenter study including 435 patients compared pazopanib to placebo with PFS 9.2 mo vs 4.2 mo respectively and ORR of 30% in predominantly clear cell RCC. A noninferiority study called COMPARZ evaluated pazopanib vs sunitinib. This showed similar efficacy profiles with different side effect profiles. PISCES, a randomized phase III trial placed patients on pazopanib 800mg qday for 10 weeks, followed by 2 weeks of placebo and then 10 weeks of sunitinb 50mg qday or vice versa. The primary endpoint was patient preference. Results of this study in predominantly clear cell histology revealed that 70% of patients preferred pazopanib, 22% preferred sunitinib and 8% had no preference. Based on these data, pazopanib has been included as first-line therapy for metastatic, non-clear cell RCC, which is reasonable for this patient.
Eric Wiedower
Jun 16, 2015
Unfortunately, the patient progressed after ~5 months of therapy. This patient was sent to MD Anderson and was placed on a clinical trial with a PD1 antibody. She tolerated this therapy well and continues to have stable disease. Immunotherapies continue to be explored any many different tumor types. ORR seem to be fairly similar, however those that respond seem to have long-lasting responses. Immunecheckpoint therapy is becoming practice changing in many fields.
Apr 19, 2024
Pending Moderator approval.
Are you sure you want to delete this comment? This can't be undone.
Sylvia
Richey
MD
Eric Wiedower
Apr 07, 2015
Eric Wiedower
Jun 16, 2015
Apr 19, 2024
Pending Moderator approval.